Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H14N3O13P3 |
| Molecular Weight | 453.1303 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1)[C@@H]2CO[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O2
InChI
InChIKey=WNZKNPIDEYYOOQ-BQBZGAKWSA-N
InChI=1S/C8H14N3O13P3/c9-5-1-2-11(8(12)10-5)6-3-20-7(22-6)4-21-26(16,17)24-27(18,19)23-25(13,14)15/h1-2,6-7H,3-4H2,(H,16,17)(H,18,19)(H2,9,10,12)(H2,13,14,15)/t6-,7-/m0/s1
DescriptionSources: DOI: 10.1007/978-1-59745-148-2_9Curator's Comment: description was created based on several sources, including:
http://www.sciencedirect.com/topics/page/Troxacitabine
http://www.docguide.com/fda-grants-orphan-drug-designation-troxatyl-troxacitabine
Sources: DOI: 10.1007/978-1-59745-148-2_9
Curator's Comment: description was created based on several sources, including:
http://www.sciencedirect.com/topics/page/Troxacitabine
http://www.docguide.com/fda-grants-orphan-drug-designation-troxatyl-troxacitabine
Troxacitabine is a synthetic nucleoside analogue. It is a poor substrate for nucleoside transporters and gains entry into cells by passive diffusion. Intracellular conversion to its active triphosphate form is via deoxycytidine kinase. Incorporation of this metabolite into DNA results in immediate chain termination and apoptosis induction. It is the first nucleoside analog with anticancer activity that has an unnatural stereochemical configuration. The dose-limiting adverse reactions were stomatitis and hand–foot syndrome.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16211462 DOI: 10.1007/978-1-59745-148-2_9 |
Primary | Unknown Approved UseUnknown |
||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16211462 DOI: 10.1007/978-1-59745-148-2_9 |
Primary | Unknown Approved UseUnknown |
||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16211462 DOI: 10.1007/978-1-59745-148-2_9 |
Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1028 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12011137 |
12.5 mg/m² single, intravenous dose: 12.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
TROXACITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3306 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12011137 |
12.5 mg/m² single, intravenous dose: 12.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
TROXACITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12011137 |
12.5 mg/m² single, intravenous dose: 12.5 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
TROXACITABINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Action of troxacitabine on cells transduced with human cytidine deaminase cDNA. | 2004 |
|
| Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines. | 2004 Aug |
|
| Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. | 2006 Apr 1 |
|
| Evaluation of the L-stereoisomeric nucleoside analog troxacitabine for the treatment of acute myeloid leukemia. | 2007 Apr |
|
| Troxacitabine in acute leukemia. | 2007 Jun |
|
| Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. | 2009 Jun |
Patents
Sample Use Guides
The recommended dose was defined as 8mg/m2/day over 30 minutes for 5 days.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
503022
Created by
admin on Sat Dec 16 15:55:43 GMT 2023 , Edited by admin on Sat Dec 16 15:55:43 GMT 2023
|
PRIMARY | |||
|
171039-00-2
Created by
admin on Sat Dec 16 15:55:43 GMT 2023 , Edited by admin on Sat Dec 16 15:55:43 GMT 2023
|
PRIMARY | |||
|
4YF9V91KCR
Created by
admin on Sat Dec 16 15:55:43 GMT 2023 , Edited by admin on Sat Dec 16 15:55:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
